Lilly teams with Medtronic on Parkinson's treatment

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients' brains with an experimental drug for Parkinson’s disease. The two companies announced their partnership on the Parkinson’s medication Tuesday morning.

Indianapolis-based Lilly has not yet begun human trials of its drug, known as a glial cell derived neurotrophic factor, or GDNF. Lilly said in a press release that it has engineered the biotech drug to distribute more broadly than other neurotrophic agents have in previous tests. Minneapolis-based Medtronic’s system, which uses a pump and catheter, supplies a steady amount of the drug to a specific brain region over time.

Financial terms of the partnership were not disclosed.

“By collaborating with Medtronic from the earliest phase of research, we are maximizing the potential for this therapy's efficient and effective development,” said Michael L. Hutton, chief scientific officer of Lilly’s neurodegeneration team, in a prepared statement.

There is no known cure for Parkinson’s, a condition caused by the loss of brain neurons that produce dopamine, a chemical messenger key to the brain’s coordination of movement. Parkinson’s patients suffer from imbalance, tremors and muscle stiffness.

Some of the most famous victims of Parkinson’s are the former boxer Muhammad Ali and actor Michael J. Fox. They are among more than 7 million estimated Parkinson’s patients worldwide.

By injecting neurotrophic factors into the brain, scientists expect that they would strengthen existing neurons, helping them produce more dopamine, said Ros Smith, senior director of regenerative biology at Lilly. Keeping neurons functioning longer could slow progression of Parkinson’s rather than treating its symptoms, as existing therapies do.

However, because neurotrophic factors are large proteins, they don’t easily cross from the bloodstream into the brain, Smith said. But Lilly scientists hope that Medtronic’s delivery system can overcome that obstacle.

"One of the most significant challenges in delivering a biologic treatment for neurodegenerative diseases is crossing the blood brain barrier. We have extensive experience in targeted drug delivery and technology that allow delivery of therapeutic agents directly to the brain,” said Dr. Steve Oesterle, senior vice president of medicine and technology at Medtronic.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. I'm sure Indiana is paradise for the wealthy and affluent, but what about the rest of us? Over the last 40 years, conservatives and the business elite have run this country (and state)into the ground. The pendulum will swing back as more moderate voters get tired of Reaganomics and regressive social policies. Add to that the wave of minority voters coming up in the next 10 to 15 years and things will get better. unfortunately we have to suffer through 10 more years of gerrymandered districts and dispropionate representation.

  2. Funny thing....rich people telling poor people how bad the other rich people are wanting to cut benefits/school etc and that they should vote for those rich people that just did it. Just saying..............

  3. Good try, Mr. Irwin, but I think we all know the primary motivation for pursuing legal action against the BMV is the HUGE FEES you and your firm expect to receive from the same people you claim to be helping ~ taxpayers! Almost all class action lawsuits end up with the victim receiving a pittance and the lawyers receiving a windfall.

  4. Fix the home life. We're not paying for your child to color, learn letters, numbers and possible self control. YOU raise your children...figure it out! We did. Then they'll do fine in elementary school. Weed out the idiots in public schools, send them well behaved kids (no one expects perfection) and watch what happens! Oh, and pray. A mom.

  5. To clarify, the system Cincinnati building is just a streetcar line which is the cheapest option for rail when you consider light rail (Denver, Portland, and Seattle.) The system (streetcar) that Cincy is building is for a downtown, not a city wide thing. With that said, I think the bus plan make sense and something I shouted to the rooftops about. Most cities with low density and low finances will opt for BRT as it makes more financial and logistical sense. If that route grows and finances are in place, then converting the line to a light rail system is easy as you already have the protected lanes in place. I do think however that Indy should build a streetcar system to connect different areas of downtown. This is the same thing that Tucson, Cincy, Kenosha WI, Portland, and Seattle have done. This allows for easy connections to downtown POI, and allows for more dense growth. Connecting the stadiums to the zoo, convention center, future transit center, and the mall would be one streetcar line that makes sense.